Charles V. Phelps

Learn More
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deace-tylase inhibitor (HDACi). Experimental Design: In this first-inhuman phase I study, quisinostat was administered orally, once daily in three weekly cycles to patients(More)
  • 1